Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PF-07258669 in Healthy Adults
NCT05113940Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-07258669 in cachexia, anorexia nervosa (AN) and Malnutrition, sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events, Number of Participants With Laboratory Test Abnormalities and 6 more. Started Nov 2021; status: completed.
02
Drugs
PF-07258669
03
Conditions
cachexiaanorexia nervosa (AN)Malnutrition
Beyond the preview
Go deeper on NCT05113940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05113940.